PTX 7.14% 4.5¢ prescient therapeutics limited

Ann: PTX to resume Clinical Trial of PTX-200 in Ovarian Cancer, page-11

  1. 16,323 Posts.
    lightbulb Created with Sketch. 746
    Agree huge potential for AML treatment, those sellers over past few months were mainly because of trial uncertainty post trial death not directly related to our drug but that is almost fully resolved with only one more trial needing FDA approval to resume. Should be be resolved before years end imo.

    None of the board (6% ownership) and institutions (36% ownership) have sold down as we are undervalued compared to peers for the trials we are undertaking. Christmas rally over 10c is on the cards imo.
 
watchlist Created with Sketch. Add PTX (ASX) to my watchlist
(20min delay)
Last
4.5¢
Change
0.003(7.14%)
Mkt cap ! $36.23M
Open High Low Value Volume
4.3¢ 4.5¢ 4.2¢ $36.38K 830.9K

Buyers (Bids)

No. Vol. Price($)
1 50000 4.4¢
 

Sellers (Offers)

Price($) Vol. No.
4.5¢ 294491 4
View Market Depth
Last trade - 16.10pm 24/07/2024 (20 minute delay) ?
PTX (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.